Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.

Takashi Saika,Tomoyasu Tsushima,Yasutomo Nasu,Yoshiyuki Miyaji,Michihisa Saegusa,Katsuji Takeda,Hiromi Kumon

Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.

2010

Takashi Saika
Tomoyasu Tsushima
Yasutomo Nasu
Yoshiyuki Miyaji
Michihisa Saegusa
Katsuji Takeda
Hiromi Kumon

Background Although transurethral resection (TUR) is the standard treatment for non-muscle-invasive bladder tumors, 40–80% of tumors recur in spite of complete resection.

Keywords:

Urology
Randomized controlled trial
Urinary bladder
Cancer
Standard treatment
Epirubicin
Bladder cancer
Urinary system
Bladder Neoplasm
Surgery
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations